首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1736432

全球甲狀腺疾病治療市場規模（按藥物類型、疾病、給藥途徑、地區和預測）

Global Thyroid Disorder Treatment Market Size By Drug Type (Levothyroxine, Liothyronine, Propylthiouracil), By Disease (Hypothyroidism, Hyperthyroidism), By Route Of Administration (Oral, Intravenous), By Geographic Scope And Forecast

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

甲狀腺疾病治療市場規模及預測

2024 年甲狀腺疾病治療市場規模價值 22 億美元，預計到 2032 年將達到 28 億美元，2026 年至 2032 年的複合年成長率為 3.17%。

甲狀腺疾病的治療包括使用甲狀腺機能低下症等疾病。這些治療旨在恢復甲狀腺激素水平並緩解症狀。
目前，甲狀腺功能亢進和甲狀腺機能低下症分別採用放射性碘和甲狀腺荷爾蒙補充療法治療。嚴重病例也可考慮手術治療。定期監測可確保有效治療。
未來，個體化醫療、標靶治療和基因編輯的進步可能成為治療的核心。新藥有可能改善療效，提供更精準的治療，同時最大限度地減少副作用。

全球甲狀腺疾病治療市場動態

影響全球甲狀腺治療市場的關鍵市場動態是：

關鍵市場促進因素

發病率不斷上升：甲狀腺甲狀腺機能低下症和甲狀腺功能亢進症等甲狀腺疾病的發病率正在上升，隨著檢測和認知的提高，對更好的治療方法的需求也日益增加。
治療進步：改進配方和個人化治療等藥物創新將提高治療的有效性和吸引力，從而推動市場成長。
人口老化：老年人患甲狀腺疾病的可能性不斷增加，這推動了對適合治療與老齡化相關的甲狀腺疾病的替代療法的需求。
獲得醫療保健：改善新興經濟體的醫療保健基礎設施和獲得醫療保健的機會將增加診斷和治療的可用性，從而推動這個以前被忽視的領域的市場成長。

主要問題

缺乏認知：對甲狀腺疾病的知識和教育不足可能會導致診斷和治療的延遲，從而降低市場潛力。
有限的訪問：農村和服務不足地區的醫療保健基礎設施不足可能會阻礙診斷和治療，從而限制市場成長。
副作用與問題：與甲狀腺疾病治療相關的副作用和問題可能會導致患者違規並降低整體市場接受度。

主要趨勢

先進的診斷：先進的診斷設備和影像技術的進步使得能夠早期準確地發現甲狀腺疾病。
生技藥品和標靶治療：生技藥品和標靶治療的開發和實施為解決甲狀腺疾病的根本原因提供了新的治療方法選擇。
遠端醫療位健康：遠端醫療和數位健康技術擴大用於遠端監控和遠端系統管理，改善患者獲得護理的機會和依從性。

Thyroid disorder treatment is controlling conditions such as hypothyroidism and hyperthyroidism using medications such as levothyroxine or antithyroid agents. These treatments are intended to restore thyroid hormone levels and reduce symptoms.
Radioactive iodine and thyroid hormone replacement therapy are currently used to treat hyperthyroidism and hypothyroidism, respectively. Surgery may be considered in severe situations. Regular monitoring enables efficient management.
In the future, treatments may center on customized medicine, targeted therapeutics and advances in gene editing. Emerging medicines may provide more precise management, improving outcomes while minimizing side effects.

Global Thyroid Disorder Treatment Market Dynamics

The key market dynamics that are shaping the global Thyroid Disorder Treatment Market include:

Key Market Drivers:

Increasing Incidence: Rising occurrences of thyroid problems, including as hypothyroidism and hyperthyroidism, are driving need for better therapies, aided by increasing detection rates and awareness.
Advancements in Treatment: Pharmaceutical innovations, such as improved medication formulations and tailored therapies, improve treatment efficacy and appeal, promoting market growth.
Aging Population: The expanding older population, which is more prone to thyroid problems, adds to the demand for therapeutic alternatives suited to age-related thyroid conditions.
Healthcare Access: Increasing healthcare infrastructure and access in emerging countries increases diagnostic and treatment availability, boosting market growth in previously neglected areas.

Key Challenges:

Lack of Awareness: Inadequate knowledge and education about thyroid problems might result in delayed diagnosis and treatment, diminishing market potential.
Limited Access: Inadequate healthcare infrastructure in rural or disadvantaged areas might impede diagnosis and treatment, limiting market growth.
Adverse Effects and Problems: Treatment side effects and problems from thyroid disorders might lead to patient noncompliance and reduce overall market acceptance.

Key Trends:

Advanced Diagnostics: Improvements in advanced diagnostic instruments and imaging techniques have resulted in earlier and more accurate detection of thyroid problems.
Biologics and Targeted Therapies: The development and implementation of biologic medications and targeted therapies to address the underlying causes of thyroid problems, hence providing new therapeutic choices.
Telemedicine and Digital Health: Telemedicine and digital health technologies are increasingly being used for remote monitoring and management, hence enhancing patient access to care and treatment adherence.

Global Thyroid Disorder Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global Thyroid Disorder Treatment Market:

North America:

According to Verified Market Research, North America is expected to dominate the global Thyroid Disorder Treatment Market.
North America is likely to lead the worldwide thyroid disease treatment market due to its sophisticated healthcare infrastructure, high prevalence of thyroid disorders and major expenditure in R&D.
The region's strong medical facilities and high levels of awareness help to maintain its leadership position, which is reinforced by ongoing advancements in treatment and diagnostics.

Asia Pacific:

According to Verified Market Research, Asia Pacific is fastest growing region in global Thyroid Disorder Treatment Market.
Asia-Pacific is the fastest-growing area in the worldwide thyroid disease treatment market, due to growing healthcare investments, rising thyroid condition prevalence and greater access to modern medical technologies. The region's high economic growth and improved healthcare facilities help to boost market expansion.

Global Thyroid Disorder Treatment Market: Segmentation Analysis

The Global Thyroid Disorder Treatment Market is segmented on the basis of Drug Type, Disease, Route of Administration, and Geography.

Thyroid Disorder Treatment Market, By Drug Type

Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based Compounds
Beta-blockers

Based on Drug Type, The market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compounds, Beta-blockers. Levothyroxine is the most common drug type in the global thyroid disease treatment market, used to treat hypothyroidism and maintain normal thyroid hormone levels.

Thyroid Disorder Treatment Market, By Disease

Hypothyroidism
Hyperthyroidism

Based on Disease, The market is segmented into Hypothyroidism and Hyperthyroidism. Hypothyroidism dominates the worldwide thyroid problem treatment market due to its higher prevalence than hyperthyroidism. The requirement for lifelong hormone replacement therapy creates increasing market demand and treatment possibilities.

Thyroid Disorder Treatment Market, By End-User

Oral
Intravenous

Based on End-User, The market is segmented into Oral and Intravenous. The oral category leads the global thyroid disease therapy market due to its convenience, ease of administration and patient preference. Oral medicines are commonly used to treat thyroid problems.

Key Players

The "Global Thyroid Disorder Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie, Inc., Mylan N.V., Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Allergan plc, Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Global Thyroid Disorder Treatment Market Recent Developments
In December 2023, Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings Limited, reached an agreement with Sandoz AG to acquire its Chinese business. This strategic move was consistent with Aspen's strategy goal of increasing its footprint in China by using Sandoz's proven portfolio, infrastructure and experienced team for future growth in the region.

1 INTRODUCTION OF GLOBAL THYROID DISORDER TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL THYROID DISORDER TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DRUG TYPE

5.1 Overview
5.2 Levothyroxine
5.3 Liothyronine
5.4 Propylthiouracil
5.5 Imidazole-based Compounds
5.6 Beta-blockers

6 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DISEASE

6.1 Overview
6.2 Hypothyroidism
6.3 Hyperthyroidism

7 GLOBAL THYROID DISORDER TREATMENT MARKET, BY END-USER

7.1 Overview
7.2 Oral
7.3 Intravenous

8 GLOBAL THYROID DISORDER TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL THYROID DISORDER TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 AbbVie, Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Mylan N.V.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Merck & Co., Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Pfizer, Inc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Abbott Laboratories
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Allergan plc
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Bayer AG
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Novartis AG
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Sanofi S.A.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 GlaxoSmithKline plc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments